Make faster, better drug development decisions
With a growing focus on inducing immune tolerance to help treat debilitating immune-mediated diseases, Beacon Immune Tolerance provides a comprehensive database of all therapies within the field.
Covering all immune tolerance therapies, immunomodulators, immunostimulants, and immunosuppressives, this solution is the one-stop-shop to help companies benchmark their assets against their competitors, and allows them to quickly keep track of the latest data in the field.
Beacon Immune Tolerance
Track the clinical trial and drug development landscape for Immune Tolerance
What we cover
Beacon Immune Tolerance covers all pharmaceutical interventions used to treat autoimmune diseases, autoinflammatory diseases, alloimmune diseases and allergies.
From small molecules to CAR T therapy, the module encapsulates all drugs and therapies within the immune-mediated disease space.
Commercial intelligence data expansion: Gain unparalleled access to in-depth company profiles and the latest commercial deals. Monitor your competitors and opportunities as well as benchmark deals and evaluate potential partners. Learn more by downloading the factsheet.
How Beacon helps
Here are a few use cases that have benefitted our clients in accelerating their immune tolerance development programs:
- Search therapeutics in the immune-disease space across all stages of development so you can accurately benchmark your strategies against all existing immune tolerance and immunomodulatory drugs, and investigate the novel technologies being used by competitors
- Drastically reduce manual research time spent looking through publications and conference abstracts for preclinical and clinical trial results by relying on our comprehensive collection of data which can be searched by a variety of options including delivery system, cell type, disease indications and much more.
- Stay on top of emerging trends and new players in the immune tolerance field with real-time updates and alerts, as well as in-depth monthly reports curated by our analyst team.
How Beacon Immune Tolerance works
All Immune Tolerance pages will have unique data fields that will help speed up the research process. These data fields include:
- Autoantigen specificity
- Mechanism of Action
- Cell Source
- Cell Type
- Delivery System
- Editing Technology
- Target Organ/Cell
- Formulation
Our unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the immune tolerance space.
How we target the data for immune tolerance
We house all publicly available sources of data updated with 24 – 48 hours of publication proactively. Our sources cover (but are not limited to):
- Clinical trials registries
- Scientific journals and publications
- Company reports and presentations
- Press releases
- Conference reports and abstracts
- Government and regulatory organizations
- Newspapers and other media
- Patents
Related content
H1 2024 Immune Tolerance Landscape Review
Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective
Beacon Immune Tolerance: 2024 EULAR Annual Meeting Abstracts
What our customers say
Beacon is a great database that people should pay attention to. It's much better than many generic databases that try to capture all data about everything.
Director
Top Biotech Company
Our Immune Tolerance Expert
Rachel Hourigan is the lead research analyst for the Immune Tolerance module.
Sign up to her weekly newsletter with the latest insights into the immunology landscape using data from Beacon Immune Tolerance.
Other Beacon Solutions
Covering all Antibody Drug Conjugates (ADCs), Small Molecule Drug Conjugates (SMDCs), Protein Drug Conjugates (PDCs), Immunotoxins and more
Covering all genetically and non-genetically engineered allogeneic and autologous cell-based therapies across all disease indications
Covering all Bi- and Multi-Specific Antibodies, Antibody Fragments, Augmented Antibodies and more
Beacon Cancer Vaccine provides the solution you need to master the prophylactic and therapeutic cancer vaccines field.
Covering all Immune Checkpoint Combination Trials and Immune Checkpoint Modulators in development across 27 different checkpoint targets
Covering all cytokines and drugs that target a cytokine or its immediate receptor belonging to the Interleukins, Interferons, Colony-stimulating factors, Transforming growth factor β, Tumour necrosis factor and Chemokines families.
Beacon DDR steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the DDR field.
From gene-editing technologies, novel delivery systems, and a variety of genetic materials being used- Beacon Gene Therapy steps into the field to give drug developers a precise and detailed view of how the gene therapy landscape looks.
Covering all pharmaceutical grade microbiome-based therapeutics across all disease indications – Beacon Microbiome provides drug developers with detailed views of the expanding microbiome landscape.
Covering Oligonucleotide-based, mRNA-Based, Ribozyme, and gRNA-Mediated Gene Editing therapies, as well as RNA-Targeted Small Molecules – Beacon RNA covers all disease indications and many modalities to provide a detailed landscape of the RNA space.
Beacon TPD provides the solution you need to master the targeted protein degradation field.
Any questions? Contact us
To learn more about how we can tailor Beacon Immune Tolerance to help you, get in touch with our sales team
About Beacon
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies and the most accurate and comprehensive life sciences data provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
